Finance

Lists
JANX:NASDAQ
Janux Therapeutics Inc
$16.64
-1.28%
(-0.22) 1D
Sep 18, 9:57:21 AM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for JANX...
Open
$16.70
High
$16.86
Low
$16.55
Mkt. cap
1.02B
Avg. vol.
843.39K
Volume
67.07K
52-wk high
$35.25
52-wk low
$12.12
EPS
-$1.64
Beta
2.53
Shares outstanding
61.14M
No. of employees
113
Open
$16.70
High
$16.86
Low
$16.55
Mkt. cap
1.02B
Avg. vol.
843.39K
Volume
67.07K
52-wk high
$35.25
52-wk low
$12.12
EPS
-$1.64
Beta
2.53
Shares outstanding
61.14M
No. of employees
113
News stories
From web sources and news partners
About Janux Therapeutics Inc
CEO-
Employees113
Founded2017
Headquarters-
SectorBiotechnology
Websitejanuxrx.com
Analyst ratings
Based on 11 analysts giving stock ratings to JANX in the past 3 months
Strong buy
Buy
10
Hold
0
Sell
1
12-month forecast
Based on 11 Wall Street analysts offering 12 month price targets for JANX in the last 3 months.
Highest
Current $16.64
$60.00 (+260.47%)
Average
$34.22 (+105.59%)
Lowest
$14.00 (-15.89%)
Analyst
Recommendation
Action
Price target
Projected
Date
Kalpit Patel
Wolfe Research
Buy
Upgraded
$23.00
+38.2%
08/24/2026
Matt Phipps
William Blair
Buy
Maintained
-
-
08/13/2026
Stephen Willey
Stifel Nicolaus
Buy
Maintained
$35.00
+110.3%
08/11/2026
Swayampakula Ramakanth
H.C. Wainwright
Buy
Maintained
$45.00
+170.4%
08/10/2026
Oliver McCammon
LifeSci Capital
Buy
Maintained
$60.00
+260.5%
08/07/2026
Supawat Thongthip
Truist Financial
Buy
Maintained
-
-
08/07/2026
Kelsey Goodwin
Piper Sandler
Buy
Maintained
$26.00
+56.2%
08/07/2026
Boris Peaker
JonesTrading
Buy
Maintained
$28.00
+68.2%
08/07/2026
Bradley Canino
Guggenheim
Buy
Reiterated
$55.00
+230.4%
08/06/2026
Alec Stranahan
Bank of America Securities
Buy
Reiterated
$22.00
+32.2%
08/07/2026
Etzer Darout
Barclays
Sell
Maintained
$14.00
-15.9%
08/07/2026
Jonathan Miller
Evercore ISI
Buy
Maintained
$22.00
+32.2%
05/11/2026
Robert Driscoll
Wedbush
Buy
Reiterated
$36.00
+116.3%
05/08/2026
Marc Frahm
TD Cowen
Buy
Maintained
-
-
05/08/2026
Unknown Analyst
Wedbush
Buy
Reiterated
$36.00
+116.3%
05/08/2026
David Dai
UBS
Hold
Downgraded
$15.00
-9.9%
04/15/2026
Soumit Roy
JonesTrading
Buy
Maintained
$50.00
+200.4%
04/06/2026
Karina Rabayeva
Truist Financial
Buy
Reiterated
$80.00
+380.6%
03/03/2026
Joshua Schimmer
Cantor Fitzgerald
Buy
Reiterated
$100.00
+500.8%
02/26/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
10.00M
-
3.73M
10.27M
Cost of goods sold
34.63M
31.55M
26.81M
30.99M
Cost of revenue
34.63M
31.55M
26.81M
30.99M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
10.62M
10.85M
11.13M
10.96M
Operating expense
10.62M
10.85M
11.13M
10.96M
Total operating expenses
45.25M
42.40M
37.95M
41.96M
Operating income
-35.25M
-42.40M
-34.21M
-31.69M
Other non operating income
-
-
-
-
EBT including unusual items
-24.31M
-31.95M
-24.36M
-21.97M
EBT excluding unusual items
-24.31M
-31.95M
-24.36M
-21.97M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-24.31M
-31.95M
-24.36M
-21.97M
Net profit margin
-243.13%
-
-652.59%
-214.01%
Earnings per share
-0.39
-0.51
-0.39
-0.35
Interest and investment income
10.94M
10.46M
9.85M
9.72M
Interest expense
-
-
-
-
Net interest expenses
10.94M
10.46M
9.85M
9.72M
Depreciation and amortization charges
-
-
-
-
EBITDA
-34.75M
-41.93M
-33.74M
-31.23M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps